These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12624661)

  • 1. Differential diagnosis of prostate lesions with the use of biomagnetic measurements and non-linear analysis.
    Anninos P; Papadopoulos I; Kotini A; Adamopoulos A
    Urol Res; 2003 Mar; 31(1):32-6. PubMed ID: 12624661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomagnetic activity in prostate cancer and BPH.
    Anninos P; Papadopoulos I; Kotini A
    Arch Esp Urol; 2008 Apr; 61(3):459-63. PubMed ID: 18581689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential diagnosis of breast lesions by use of biomagnetic activity and non-linear analysis.
    Anninos PA; Kotini A; Koutlaki N; Adamopoulos A; Galazios G; Anastasiadis P
    Eur J Gynaecol Oncol; 2000; 21(6):591-5. PubMed ID: 11214617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of non-linear analysis for differentiating the biomagnetic activity in ovarian lesions.
    Anninos PA; Anastasiadis P; Kotini A
    J Obstet Gynaecol; 1999 May; 19(3):280-5. PubMed ID: 15512296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
    Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
    Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomagnetic activity in ovarian lesions.
    Anastasiadis P; Anninos P; Kotini A; Limberis B; Galazios G
    Anticancer Res; 1998; 18(5B):3753-6. PubMed ID: 9854489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
    Chen ZD; Wei SM; Cai SL
    Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
    Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
    Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy.
    Kurhanewicz J; Vigneron DB; Nelson SJ; Hricak H; MacDonald JM; Konety B; Narayan P
    Urology; 1995 Mar; 45(3):459-66. PubMed ID: 7533458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age?
    Bastian PJ; Ellinger J; Schmidt D; Wernert N; Wellmann A; Müller SC; von Rücker A
    Eur J Med Res; 2004 Nov; 9(11):523-7. PubMed ID: 15649863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer].
    Meguro N; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
    Hinyokika Kiyo; 1998 Sep; 44(9):639-43. PubMed ID: 9805668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiation between benign prostatic hyperplasia and prostate cancer in the transitional zone evaluated by 1H magnetic resonance spectroscopic imaging.
    Li SY; Chen M; Wang R; Zhou C
    Chin Med Sci J; 2007 Dec; 22(4):238-42. PubMed ID: 18246671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-parametric MRI findings of transitional zone prostate cancers: correlation with 3-dimensional transperineal mapping biopsy.
    Pokharel SS; Patel NU; Garg K; La Rosa FG; Arangua P; Jones C; Crawford ED
    Abdom Imaging; 2015 Jan; 40(1):143-50. PubMed ID: 25038718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
    De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
    Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomagnetic measurements in uterine leiomyomas using a superconducting quantum interference device (SQUID).
    Anastasiadis PG; Anninos PA; Koutsougeras GC; Liberis VA; Galazios GC; Sivridis EL
    Int J Gynaecol Obstet; 1989 May; 29(1):47-9. PubMed ID: 2566528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of cyclooxygenase-2 over expression for identifying prostate cancer from benign prostatic hyperplasia in prostate biopsy specimens.
    Ceylan Y; Lekili M; Muezzinoglu T; Nese N; Isisag A
    Minerva Urol Nefrol; 2016 Jun; 68(3):255-62. PubMed ID: 26125280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of PSAD and PSAD-TZ value in prostatic hyperplasia and prostatic cancer].
    Fu Q; Yao DH; Jiang YQ
    Zhonghua Nan Ke Xue; 2002 Dec; 8(6):411-3. PubMed ID: 12593013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.